Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS-PTP1BRx · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ISIS-PTP1BRx | EXPERIMENTAL | Weekly Dosing for 26 Weeks |
| Placebo | PLACEBO_COMPARATOR | Weekly Dosing for 26 Weeks |
| Name | Type | Description |
|---|---|---|
| ISIS-PTP1BRx | DRUG | - |
| Placebo | DRUG | - |
| daily OAD (metformin and/or sulfonylurea) | DRUG | - |
Inclusion Criteria: * Body mass index (BMI) \>/= 27 kg/m2 * HbA1c between 7.5% and 10.5% (inclusive) * C-Peptide (fasting) greater than or equal to 500 pmol/L * On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \>/= 3 months prior to screening, and remain on...
ISIS-PTP1BRx is an investigational drug being studied for the treatment of Type 2 Diabetes Mellitus. It is a small molecule being developed by Ionis Pharmaceuticals, Inc. (IONS) and is currently in Phase 2 clinical development for this metabolic condition.
ISIS-PTP1BRx is an antisense oligonucleotide that targets PTP1B, a protein tyrosine phosphatase involved in insulin signaling. By inhibiting PTP1B, the drug aims to enhance insulin sensitivity and improve glycemic control in patients with Type 2 Diabetes Mellitus.
ISIS-PTP1BRx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety and efficacy of this drug in patients with Type 2 Diabetes Mellitus.
ISIS-PTP1BRx is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its safety, tolerability, and efficacy in patients with Type 2 Diabetes Mellitus.
ISIS-PTP1BRx has been studied in a Phase 2 clinical trial registered as NCT01918865, titled "Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes." This randomized, double-blind, placebo-controlled trial enrolled 92 participants with Type 2 Diabetes Mellitus and obesity, and was conducted in Argentina, Canada, and South Africa.
ISIS-PTP1BRx is a specific antisense oligonucleotide targeting PTP1B, distinct from small-molecule PTP1B inhibitors. It is being developed by Ionis Pharmaceuticals for Type 2 Diabetes Mellitus, and its mechanism involves reducing PTP1B expression to improve insulin signaling.